



Annual Report and Audited Financial Statements for the year ended 30 June 2023



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

Contents	Page
General Information	3
Investment Manager's Report	4
Directors' Report	6
Independent Auditor's Report	8
Custodian's Report	11
Supplementary Information	12
Portfolio Statement	13
Statement of Financial Position	14
Statement of Comprehensive Income	15
Statement of Cash Flows	16
Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares	17
Notes to the Financial Statements	18



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **General Information**

#### **Address and Registered Office**

PO Box 255 Trafalgar Court, Les Banques St Peter Port, Guernsey GY1 3QL

Channel Islands

### **Investment Manager**

Momentum Global Investment Management Limited Administration The Rex Building 62 Queen Street London EC4R 1EB United Kingdom

#### **Distribution Partner**

PMK Consulting Services (Pty) Ltd Unit 4 Oaktree Corner 9 Kruger Street Oaklands, Johannesburg 2192 South Africa

#### Manager

Momentum Wealth International Limited La Plaiderie House La Plaiderie St Peter Port, Guernsey GY1 1WF Channel Islands

### Custodian

Northern Trust (Guernsey) Limited PO Box 71 Trafalgar Court Les Banques St Peter Port, Guernsey GY1 3DA Channel Islands

### **Directors of the Incorporated Cell**

Robert Alastair Rhodes Roxanne Power Marie Curutchet Ferdinand van Heerden Kapil Joshi – resigned 25 May 2023 Ray Mhere – appointed 25 May 2023

### Administrator, Registrar & Secretary

Northern Trust International Fund Services (Guernsey) Limited PO Box 255 Trafalgar Court Les Banques St Peter Port, Guernsey GY1 3QL Channel Islands

#### **Legal Advisor**

Carey Olsen
Carey House
Les Banques
St Peter Port, Guernsey
GY1 4BZ
Channel Islands

### **Independent Auditor**

Ernst & Young LLP PO Box 9 Royal Chambers St Julian's Avenue St Peter Port, Guernsey GY1 4AF Channel Islands



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

### **Investment Manager's report**

Equity markets rallied during the second quarter as inflation eased, the United States Federal Reserve (the "Fed") paused rate hikes, the banking sector stabilised and technology stocks rebounded strongly.

Developed markets generated strong performance whilst emerging markets lagged, particularly China. Japan was the strongest performing region in local currency terms (up 14%) due to ongoing expectations of corporate governance reforms and structural shifts in the economy, combined with a weakening currency. The US was the next top performer (up 9%) with the majority of these gains coming from just seven mega-cap technology stocks which disproportionately benefitted from the hype around artificial intelligence ("AI"). Other factors driving positive returns in the region were the Fed's pause in June following ten consecutive interest rate hikes, and better than expected GDP growth.

Most sectors posted positive gains over the quarter but technology (14%) and consumer discretionary (10%) led the way. Utilities and energy (both down -1%) were the worst performing sectors and small-caps lagged large-caps which is unsurprising given the dominant performance of mega-cap technology.

Although Latin America posted strong positive gains during the period (14%), emerging market returns were muted (MSCI Emerging Markets index up just 1% in dollar terms) because China is a large constituent and the region underperformed significantly (-10%). Key factors were the tensions between the US and China and fading optimism regarding China's recovery following the initial post-lockdown boom.

Global government bonds underperformed during the second quarter (-2%). With the exception of the Bank of Japan, all major central banks continued to raise interest rates in the fight to tame inflation. The Bank of England had to act aggressively, raising rates by 50bps as inflation is proving to be particularly sticky in the UK. The Fed decided to pause in June, raising hopes of a soft landing, however additional hikes are still expected.

Global high yield outperformed global investment grade as near-term recessionary fears abated and corporate balance sheets proved resilient for the most part.

The fund was flat for the quarter but nonetheless outperformed global bonds. Within equities, it has been difficult for our active managers to add value, given the index is currently skewed towards a small number of stocks within a single sector and with increasingly rich valuations. In order to overweight these mega-cap technology stocks, our managers would need to be heavily concentrated in one sector, which comes with significant risk. Additionally, the strong performance of these stocks meant that after a strong start to the year, value tilted managers lagged and this had a knock on effect in the portfolio.

Within emerging market equities, our dedicated China manager, Bin Yuan, generated negative performance. The region suffered from the aforementioned headwinds and the fund is underweight in both technology stocks – which benefitted from the hype around AI – and state-owned-enterprises which have benefited from bearish sentiment.

Our underweight allocation to fixed income was positive, however manager selection detracted. In particular, the Ashmore Emerging Markets High Yield Debt Fund suffered due to negative sentiment towards China where the fund is overweight. Concerns around the distressed debt portion of the portfolio in the current macro climate weighed on performance, however the portfolio is cheap today in our view and hence there is significant upside potential.

Real assets performance did little to move the dial overall during the period and the fund's underlying property and infrastructure managers delivered mixed performance relative to their respective benchmarks.

Over 12 months the fund has returned 2.9%, thanks to strong returns from global equities. Positioning within fixed income benefitted performance, in particular the fund's underweight to duration and overweight allocation to asset-backed securities, via the TwentyFour Income Fund. The key detractor was manager selection within equity: our core equity blend underperformed the MSCI World Index by 1.6%, while the share price performance of our private equity managers was also weak.

Latest changes in the fund include adding to duration as we are seeing more value in fixed income on a long term view. Note that the portfolio remains slightly underweight as we are not yet bullish on the asset class and anticipate headwinds in the short term.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

## **Investment Manager's report (continued)**

Post year end we also added a small position in the Round Hill Music Royalties investment trust (1%) because we have a positive long term view of the strategy which has experienced short term headwinds such as concerns around the music streaming industry in the current market environment. However, the industry continues to see strong growth and this investment adds a differentiated return stream to the other assets in the portfolio.

The manager line-up in the fund and the asset class mix continues to offer a good level of diversification that should see us through various market environments and cycles.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

### **Directors' Report**

The Directors present their annual report together with the audited financial statements of PMK Wealth Global Cautious Fund IC Limited (the "Incorporated Cell" or "Cell") for the year ended 30 June 2023.

#### **Principal activities**

The Cell with company number 65991 is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company"). The activities and objectives of the Cell can be found in note 1 on page 18.

#### **Going concern**

The Directors have made an assessment of going concern including consideration of geopolitical issues on the Cell. Refer to note 2 for the detailed disclosure.

#### **Directors**

The Directors of the Cell during the year and at the date of this report are set out on page 3.

#### **Directors' interests**

None of the Directors who held office during the period and at the date of this report had any disclosable interests in the shares of the Incorporated Cell.

#### Directors' responsibilities

The Directors are responsible for preparing the financial statements for each financial year, which give a true and fair view, in accordance with applicable Guernsey law and International Financial Reporting Standards, of the state of affairs of the Incorporated Cell and of the profit or loss of the Cell for that period. In preparing these financial statements the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on a going concern basis, unless it is inappropriate to presume that the Incorporated Cell will continue in business.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.

The Directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Incorporated Cell and enable them to ensure that the financial statements comply with The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020. They are also responsible for safeguarding the assets of the Incorporated Cell and hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as each Director is aware, there is no relevant audit information of which the Incorporated Cell auditor is unaware and each Director has taken all the steps they ought to have as a Director to make themselves aware of any relevant audit information and to establish that the Incorporated Cell's auditor is aware of that information.

The Board of Directors confirms that, throughout the period covered by the financial statements, the Cell complied with the Code of Corporate Governance issued by the Guernsey Financial Services Commission, to the extent it was applicable based upon its legal and operating structure and its nature, scale and complexity.

The annual report together with the audited financial statements of the Incorporated Cell are published on the Manager's website. The Manager is responsible for the maintenance and integrity of the website; the work carried out by the auditor does not involve consideration of these matters and, accordingly, the auditor accepts no responsibility for any changes that may occur to the financial statements after they are initially presented on the website. The Directors appreciate there is uncertainty regarding legal requirements of information published on the internet as it is accessible in many countries and legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

## **Directors' Report**

## **Independent auditors**

Ernst &Young LLP have indicated their willingness to continue in office. The reappointment of Ernst &Young LLP will be proposed within the next written resolution to deal with annual business.

**Marie Curutchet** 

Director

30 November 2023

**Robert Rhodes** 

Director



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

### Independent Auditor's Report to the Members of PMK Wealth Global Cautious Fund IC Limited

#### **Opinion**

We have audited the financial statements of PMK Wealth Global Cautious Fund IC Limited (the "Incorporated Cell") for the year ended 30 June 2023 which comprise the Statement of Financial Position, the Statement of Comprehensive Income, the Statement of Cash Flows, the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares, and the related notes 1 to 17, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards.

In our opinion, the financial statements:

- give a true and fair view of the state of the Incorporated Cell's affairs as at 30 June 2023 and of its profit for the year then ended:
- · have been properly prepared in accordance with International Financial Reporting Standards; and
- have been properly prepared in accordance with the requirements of The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Incorporated Cell in accordance with the ethical requirements that are relevant to our audit of the financial statements, including the UK FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Incorporated Cell's ability to continue as a going concern for the period to 31 December 2024.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Incorporated Cell's ability to continue as a going concern.

## Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### Independent Auditor's Report to the Members of PMK Wealth Global Cautious Fund IC Limited (continued)

#### Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which The Companies (Guernsey) Law, 2008 requires us to report to you if, in our opinion:

- proper accounting records have not been kept by the Incorporated Cell; or
- the financial statements are not in agreement with the Incorporated Cell's accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

### **Responsibilities of directors**

As explained more fully in the directors' responsibilities statement set out on page 6, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Incorporated Cell's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Incorporated Cell or to cease operations, or have no realistic alternative but to do so.

### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

### Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.

- We obtained an understanding of the legal and regulatory frameworks that are applicable to the Incorporated Cell and determined that the most significant are those that relate to the reporting framework (International Financial Reporting Standards, The Companies (Guernsey) Law, 2008 and the Protection of Investors (Bailiwick of Guernsey) Law, 2020);
- We understood how the Incorporated Cell is complying with those frameworks by making enquiries of management and
  those responsible for compliance matters and corroborated this by reviewing minutes of meetings of the Board of
  Directors and correspondence between the Incorporated Cell and the Guernsey Financial Services Commission. We
  gained an understanding of the Board's approach to governance, demonstrated by its review of compliance reports, the
  investment manager's reports and internal control processes;



Annual Report and Audited Financial Statements for the year ended 30 June 2023

Independent Auditor's Report to the Members of PMK Wealth Global Cautious Fund IC Limited (continued)

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud (continued)

- We assessed the susceptibility of the Incorporated Cell's financial statements to material misstatement, including how fraud might occur by considering the risk of management override and by identifying the valuation of investments (specifically manual price overrides) and the recognition of dividend income at year-end (cut-off) as fraud risks. We considered the controls the Incorporated Cell has established to address the risk identified by the directors or that otherwise seek to prevent, detect or deter fraud and how management and those charged with governance monitor those controls. We also considered the existence of any stakeholder influences which may cause management to seek to manipulate the financial performance and did not note any;
- Based on this understanding we designed our audit procedures to identify non-compliance with such laws and regulations. Our procedures involved the review of minutes of meetings of the Board of Directors; review of compliance reports; review of correspondence with the Guernsey Financial Services Commission; making inquiries of those charged with governance; and performance of journal entry testing based on our risk assessment and understanding of the business, with a focus on non-standard journals and those relating to areas with an identified associated fraud risk, as described above.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

#### Use of our report

This report is made solely to the Incorporated Cell's members, as a body, in accordance with Section 262 of The Companies (Guernsey) Law 2008 and Paragraph 4.2(4) of the Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021. Our audit work has been undertaken so that we might state to the Incorporated Cell's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Incorporated Cell and the Incorporated Cell's members as a body, for our audit work, for this report, or for the opinions we have formed.

DocuSigned by:

Ensil Varill 4753914588A54C3

Ernst & Young LLP
Guernsey, Channel Islands

Date: 04 December 2023



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

## Custodian's Report to the Members of PMK Wealth Global Cautious Fund IC Limited

In our opinion, the Cell has, in all material aspects, been managed for the year ended 30 June 2023 in accordance with the provisions of the Principal Documents, Scheme Particulars and The Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021.

For and on behalf of

**Northern Trust (Guernsey) Limited** 

**30 November 2023** 



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

## **Supplementary Information**

		30.06.23	30.06.22
1.	NUMBER OF SHARES OUTSTANDING		
	Class A	10,683,398	11,065,256
	Class C	1,698,501	774,444
2.	NET ASSET VALUE PER SHARE - USD		
	Class A	1.01	0.97
	Class C	0.90	0.88
3.	HIGHEST/LOWEST PRICE - USD*		
	Class A	1.02/0.91	1.14/0.97
	Class C	0.92/0.82	1.03/0.88
4.	NUMBER OF SHARES SUBSCRIBED		
	Class A	128,399	1,977,273
	Class C	926,982	443,086
5.	NUMBER OF SHARES REDEEMED		
	Class A	510,257	1,531,258
	Class C	2,925	-

<sup>\*</sup>The highest/lowest price is based on prices from prior year to current year end, being 30.06.2023.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

## **Portfolio Statement**

			% of Net
	Holdings	Fair Value	Assets
Financial assets at fair value through profit or loss		<u>USD</u>	
Government Bonds 21.53% (2022: 15.32%)			
United States Treasury Inflation Indexed Bonds 0.625% 15/02/2043	790,000	856,126	6.97
United States Treasury Note/Bond 1.625% 15/08/2029	770,000	671,675	5.47
United States Treasury Note/Bond 2.125% 31/05/2026	610,400	571,010	4.65
United States Treasury Note/Bond 2.25% 15/08/2049	750,000	545,391	4.44
Total Government Bonds	´ -	2,644,202	21.53
	_		
Collective Investment Schemes 68.8% (2022: 71.51%)			
Commodity Funds			
Commodity Funds iShares Gold Producers UCITS ETF	12 020	158,364	1.29
iShares Physical Gold ETF	12,020 15,585	581,788	1.29 4.74
•	13,363		
Total Commodity Funds		740,152	6.03
Equity Funds			
Bin Yuan Greater China Fund	727	98,635	0.80
Fidelity Funds - Emerging Markets Fund	14,068	200,610	1.63
Maple-Brown Abbott Global Infrastructure Fund	87,391	138,943	1.03
Momentum GF Global Equity Fund	15,626	2,841,205	23.13
Morant Wright Fuji Yield Fund	22,758	329,737	23.13
Sands Capital Funds - Sands Emerging Markets Growth Fund	8,223	118,994	0.97
Schroder Recovery Fund - Z Accumulating	108,056	182,437	1.48
	100,030_		<del></del>
Total Equity Funds		3,910,561	31.83
Fixed Income Funds			
Ashmore SICAV Emerging Markets Asian High Yield Debt Fund	2,402	113,210	0.92
AXA IM Fixed Income Investment Strategies - US Short Duration High Yield	1,944	419,422	3.41
Dodge & Cox Worldwide Funds - Global Bond Fund	72,366	913,255	7.43
Institutional Cash Series - Institutional US Dollar Ultra Short Bond Fund	4,225	478,933	3.90
iShares \$ TIPS UCITS ETF	1,695	390,138	3.18
Jupiter Global Emerging Markets Short Duration Bond	4,808	536,131	4.36
Muzinich Funds - Enhanced Yield Short-Term Fund	3,018	584,850	4.76
SPDR Bloomberg China Treasury Bond UCITS ETF	13,000	365,916	2.98
Total Fixed Income Funds	_	3,801,855	30.94
	_		
Total Collective Investment Schemes	_	8,452,567	68.80
Property and Infrastructure Investment Trusts and ETFs 9.36% (2022: 12.96%)			
iShares Developed Markets Property Yield ETF USD Dist	6,950	151,510	1.23
Digital 9 Infrastructure Fund	65,000	50,574	0.41
Gore Street Energy Storage Fund	52,792	62,956	0.51
Merian Chrysalis Investment Company Limited	70,000	61,050	0.50
Schroder UK Public Private Trust	320,000	51,057	0.42
Sequoia Economic Infrastructure Income Fund	423,292	413,301	3.36
TwentyFour Income Fund	280,000	360,001	2.93
Total Property and Infrastructure Investment Trusts and ETFs	_	1,150,449	9.36
• •	_		
Financial assets at fair value through profit or loss		12,247,218	99.69
Other Net Assets 0.31% (2022: 0.21%)		38,124	0.31
Net Assets Attributable to Holders of Participating Redeemable Shares	<del>-</del>	12,285,342	100.00
	_		



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

## **Statement of Financial Position**

		Year ended 30.06.23	Year ended 30.06.22
	Notes	<u>USD</u>	<u>USD</u>
ASSETS			
CURRENT ASSETS			
Financial assets at fair value through profit or loss	6	12,247,218	11,416,774
Cash and cash equivalents	7	36,969	-
Securities sold receivable		24,130	167,004
Dividend receivable		1,007	1,025
Bond interest receivable		14,570	8,055
Deposit interest receivable		120	-
Other receivables	8	566	1,857
Fair value of derivative financial instruments	9	-	22,215
Total assets	=	12,324,580	11,616,930
LIABILITIES			
CURRENT LIABILITIES			
Bank overdraft	7	-	145,557
Due on redemption of participating redeemable shares		-	662
Fair value of derivative financial instruments	9	13,475	-
Other payables	10	25,663	24,722
Securities purchased payable		-	4,370
Liabilities (excluding net assets attributable to holders of	-		
participating redeemable shares)	_	39,138	175,311
Net assets attributable to holders of participating redeemable shares	3 & 12	12,285,342	11,441,519
Total liabilities	-	12,324,480	11,616,830
SHAREHOLDERS' EQUITY			
Management shares	11	100	100
Total equity	-	100	100
Total equity and liabilities	_	12,324,580	11,616,930
	=		
Net asset value per participating redeemable share			
Class A USD Shares	12	1.01	0.97
Class C USD Shares	12	0.90	0.88

The notes 1 to 17 on pages 18 to 33 form part of these financial statements.

These financial statements were authorised for issue by the Board of Directors on 30 November 2023 and signed on its behalf by:

**Marie Curutchet** 

Director

Robert Rhodes Director

Page 14 of 33



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

## **Statement of Comprehensive Income**

	Notes	Year ended 30.06.23 <u>USD</u>	Year ended 30.06.22 <u>USD</u>
INCOME			
Net realised (losses)/gains on financial assets at fair value through profit			
or loss	6	(103,252)	147,800
Change in unrealised gains/(losses) on financial assets at fair value			
through profit or loss	6	604,775	(1,852,117)
Net gains/(losses) on financial assets at fair value through profit or loss		501,523	(1,704,317)
Deposit interest		1,528	-
Bond interest		30,456	19,662
Dividend income		105,418	67,878
Other foreign exchange (losses)/gains		(3,210)	173,906
Net losses on forward derivative contracts	_	(73,806)	(105,063)
Total net income/(loss)	_	561,909	(1,547,934)
OPERATING EXPENSES			
Audit fee		(10,144)	(8,642)
Custodian fee	14	(7,813)	(12,072)
Distribution Partner fee	14	(47,837)	(46,563)
Investment Management fee	14	(42,186)	(44,887)
Management and Administration fee	14	(36,159)	(38,499)
Finance cost		-	(306)
Sundry expenses		(9,696)	(11,242)
Total operating expenses	_	(153,835)	(162,211)
Net profit/(loss) before tax		408,074	(1,710,145)
Increase/(decrease) in net assets attributable to holders of participating redeemable shares from operations	=	408,074	(1,710,145)

All items in the above statement derive from continuing operations. There is no difference between the increase/(decrease) in net assets attributable to holders of participating redeemable shares and comprehensive income.

The notes 1 to 17 on pages 18 to 33 form part of these financial statements.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

## **Statement of Cash Flows**

	Year ended 30.06.23 <u>USD</u>	Year ended 30.06.22 <u>USD</u>
CASH FLOW FROM OPERATING ACTIVITIES		
Increase/(decrease) in net assets attributable to holders of participating		
redeemable shares from operations	408,074	(1,710,145)
ADJUSTMENT FOR:		
Net realised losses/(gains) on financial assets at fair value through profit or loss	103,252	(147,800)
Net unrealised (gains)/losses on financial assets at fair value through profit or loss	(604,775)	1,852,117
Net losses on forward derivative contracts	73,806	105,063
Effect of foreign exchange rate on cash	(1,020)	513
Dividend income	(105,418)	(67,878)
Bond interest	(30,456)	(19,662)
Deposit interest	(1,528)	306
Operating loss before working capital changes	(158,065)	12,514
Net decrease in interest receivable	-	18,691
Net decrease in other receivables	1,291	996
Net increase/(decrease) in other payables	948	(495)
Purchase of financial assets at fair value through profit or loss	(3,256,397)	(5,394,291)
Sale of financial assets at fair value through profit or loss	3,065,979	3,738,928
Net settlement of forward derivative contracts	(38,122)	(94,506)
Dividends received	105,436	66,853
Bond interest received	23,941	-
Deposit interest received/(paid)	1,408	(306)
Net cash used in operating activities	(253,581)	(1,651,616)
CACH FLOW, FROM FINANCING ACTIVITIES		
CASH FLOW FROM FINANCING ACTIVITIES  Cash received from issuance of participating redeemable shares	933,335	2,582,547
Cash paid on redemption of participating redeemable shares	(498,248)	(1,563,714)
Net cash generated from financing activities	435,087	1,018,833
Net cash generated from imancing activities	433,067	1,010,033
Net increase/(decrease) in cash and cash equivalents	181,506	(632,783)
Cash and cash equivalents at the beginning of the year	(145,557)	487,739
Effect of foreign exchange rate on cash	1,020	(513)
Cash and cash equivalents at the end of the year	36,969	(145,557)

The notes 1 to 17 on pages 18 to 33 form part of these financial statements.



Annual Report and Audited Financial Statements for the year ended 30 June 2023

## Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares

		Year ended	Year ended
	Notes	30.06.23	30.06.22
		<u>USD</u>	<u>USD</u>
Net assets attributable to holders of participating redeemable shares at the			
beginning of the year		11,441,519	12,132,831
Proceeds receivable from issuance of participating redeemable shares		933,335	2,582,547
Payments on redemption of participating redeemable shares		(497,586)	(1,563,714)
Increase/(decrease) in net assets attributable to holders of participating			
redeemable shares from operations		408,074	(1,710,145)
Net assets attributable to holders of participating redeemable shares at the end of the year	12	12,285,342	11,441,519

The notes 1 to 17 on pages 18 to 33 form part of these financial statements.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 1. General information

PMK Wealth Global Cautious Fund IC Limited (the "Incorporated Cell" or "Cell"), with company numbers 65991 is a Guernsey registered, Limited Liability Incorporated Cell of the Momentum Mutual Fund ICC Limited (the "Company"). The Cell was incorporated on 29 January 2019.

The Cell is designed to deliver a real return of US CPI +2.5% net of fees over the medium to long term, with an appropriate level of risk. The Cell intends to achieve its investment objective by investing globally, primarily via other Collective Investment Schemes, in a wide range of asset classes including cash, fixed income, equities, property, commodities and asset allocation portfolios.

The Cell may also invest in transferable securities which are classes of investments that are negotiable on a capital market such as (but not limited to) shares in companies or bond investments.

The Cell's investment activities are managed by Momentum Wealth International Limited (the "Manager") with the investment management delegated to Momentum Global Investment Management Limited (the "Investment Manager").

On 18 July 2022, amendments were made to the Supplemental Prospectus of the Cell, which were as follows:

- Changes to the initial US\$1.00 offer price on Class C shares to prices reflecting the NAV per share at any applicable Valuation Point.
- Regulatory position- explanation was added to the effect that the Cell has been approved for promotion in South Africa by the Financial Sector Conduct Authority of South Africa.

#### 2. Summary of significant accounting policies

The principal accounting policies detailed below have been consistently applied in the preparation of the financial statements.

#### 2.1 Basis of preparation

The financial statements for the Incorporated Cell have been prepared on a going concern basis, in accordance with International Financial Reporting Standards ("IFRS"). The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss (including derivative financial instruments).

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates, which are disclosed in note 4 of these Incorporated Cell's financial statements. It also requires the Board of Directors to exercise its judgement in the process of applying the Incorporated Cell's accounting policies.

### Going concern

At the time of approving the financial statements, the Board has assessed redemption levels and there have been no significant redemptions. The Board has also considered the liquid nature of the investment portfolio, the absence of any borrowings or commitments and the economic viability of the Cell which is driven by its net asset value.

After careful consideration, the Board is satisfied that the Cell has sufficient liquidity to meet its liabilities for the period to 31 December 2024 and therefore it is appropriate to adopt the going concern basis in preparing the financial statements and they have a reasonable expectation that the Cell will continue in existence as a going concern.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 2. Summary of significant accounting policies (continued)

#### 2.2 Adoption of new and revised standards

The Directors have adopted a policy of applying new standards and interpretations when they become effective.

Standards, amendments and interpretations effective during the year

The following accounting standards, amendments and interpretations became effective for the first time in this reporting period:

Periods beginning on or after 1 January 2022:

(a) IFRS 9 - Fees in the '10 per cent ' Test for Derecognition of Financial Liabilities - Amendment to clarify the fees a company includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability.

The adoption of this standard has not had a material impact on the financial statements of the Incorporated Cell.

(b) IFRS 3 - Updating a Reference to the Conceptual Framework - Amendments updated IFRS 3 by replacing a reference to an old version of the Board's Conceptual Framework for Financial Reporting with a reference to the latest version. The adoption of this standard has not had a material impact on the financial statements of the Incorporated Cell.

The adoption of this standard has not had a material impact on the financial statements of the Incorporated Cell.

Standards, amendments and interpretations in issue not yet effective

A number of new Standards, amendments and interpretations are effective for annual periods beginning on or after 1 January 2023 and have not been early adopted in preparing these financial statements. These include:

- (a) IAS 1 Definition of Accounting Estimates(Amendments to IAS 8) Effective from 1 January 2023 Amendments regarding classification of liabilities and disclosure of accounting policies.
- (b) IAS 1 Disclosure Initiative Accounting Policies Effective from 1 January 2023 Amendments to help entities apply materiality judgements to accounting policy disclosure.

The Board anticipates that the adoption of these standards, which will be adopted in the period which they become effective, will not have a material impact on the financial statements of the Cell.

#### 2.3 Foreign currency translation

(a) Functional and presentation currency

The currency in which the financial information is shown in the financial statements of the Incorporated Cell is deemed to be its functional and presentational currency. In arriving at the functional currency, the Directors have considered the primary economic environment of the Incorporated Cell, and in doing so, have considered the currency in which the original capital was raised, any distributions are to be made, performance is evaluated and ultimately, the currency in which capital would be returned on break up basis. They have also considered the currency to which the majority of the underlying investments are exposed, and liquidity is managed. The Directors are of the opinion that the currency selected best represent the functional currency.

(b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income. Translation differences on non-monetary financial assets and liabilities such as equities at fair value through profit or loss are recognised in the Statement of Comprehensive Income within the fair value net gain or loss.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 2. Summary of significant accounting policies (continued)

#### 2.4 Financial assets and financial liabilities at fair value through profit or loss

#### (a) Classification

The Incorporated Cell classifies its investments in Collective Investment Schemes, equities and related derivatives as financial assets or financial liabilities at fair value through profit or loss. These financial assets and financial liabilities are classified by the Board of Directors at fair value through profit or loss at inception. The Incorporated Cell does not classify any derivatives as hedges in a hedging relationship. Financial assets and financial liabilities are designated at fair value through profit or loss at inception, are managed, and their performance evaluated on a fair value basis in accordance with the Incorporated Cell's documented investment strategy. The Incorporated Cell's policies are for the Investment Manager and the Board of Directors to evaluate the information about these financial assets on a fair value basis together with other related financial information.

#### (b) Recognition/derecognition

Regular-way purchases and sales of investments are recognised on the trade date of the underlying security, so long as the underlying transaction has been confirmed by the relevant counterparty as at the Statement of Financial Position date. Investments are derecognised when the rights to receive cash flows from the investments have expired or the Incorporated Cell has transferred substantially all risks and rewards of ownership.

#### (c) Measurement

Financial assets and financial liabilities at fair value through profit or loss are initially recognised at fair value. Transaction costs are expensed in the Statement of Comprehensive Income of the Incorporated Cell. Subsequent to initial recognition, all financial assets and financial liabilities at fair value through profit or loss are measured at fair value. Gains and losses arising from changes in the fair value of the 'financial assets or financial liabilities at fair value through profit or loss' category are presented in the Statement of Comprehensive Income in the period in which they arise.

### (d) Fair value estimation

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets (such as publicly traded derivatives and trading securities) are based on quoted market prices at the close of trading on the reporting date. The Incorporated Cell adopted to utilise the last traded market price for both financial assets and financial liabilities where the last traded price falls within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, management will determine the point within the bid-ask spread that is most representative of fair value. As a practical expedient to establish fair value within the bid-ask spread, management will use mid-market pricing. The market price used for assets which are not traded in active markets are those as supplied by its fund administrators.

#### 2.5 Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously.

### 2.6 Forward currency contracts

Forward foreign currency contracts are treated as derivative contracts and as such are recognised at fair value on the date on which they are entered into and subsequently remeasured at their fair value. Fair value is determined by rates in active currency markets. All derivatives are carried as assets when fair value is positive and as liabilities when fair value is negative. The gain or loss on remeasurement to fair value is recognised immediately through profit or loss in the Statement of Comprehensive Income within other losses and gains in the period in which they arise.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

### 2. Summary of significant accounting policies (continued)

#### 2.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts.

#### 2.8 Other financial instruments

For other financial instruments, including amounts due to and from brokers and all receivables and payables, the carrying amounts as shown in the Statement of Financial Position approximate to fair value due to the short-term nature of these financial instruments.

#### 2.9 Share capital

The Incorporated Cell has an authorised share capital of 100 management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

#### (a) Management shares

Management shares were issued to comply with Guernsey Company Law, prior to its revision in 2008, under which there had to be a class of non-redeemable shares in issue in order that participating redeemable shares may be issued. The management shares are beneficially owned by the Manager, do not carry any right to dividends, are only entitled to vote at shareholder meetings where there are no participating redeemable shares in issue within the Incorporated Cell and are only entitled to return of capital on the winding up of the Incorporated Cell.

The Incorporated Cell has issued 100 management shares.

#### (b) Participating redeemable shares

The Incorporated Cell's capital is represented by participating redeemable shares with no par value each carrying one vote, no matter which share class. Each share class carries identical rights, the only difference between the classes being either the management fee or the distribution partner fee which is charged to each class. These fees are disclosed in note 14.

The participating redeemable shares are redeemable at the holder's option and are classified as financial liabilities. Participating redeemable shares can be put back to the Incorporated Cell at any time for cash equal to a proportionate share of the Incorporated Cell's net asset value. The participating redeemable share is carried at the redemption amount that is payable at the Statement of Financial Position date if the holder exercises the right to put the share back to the Incorporated Cell.

All participating redeemable shares will rank equally for all dividends and other distributions, as adjusted to reflect any differences in the fees to which each class of participating redeemable share is subject. They are entitled to payment of a proportionate share based on the Cell's net asset value per share on the redemption date. The Cell has no restrictions or specific capital requirements on the subscriptions and redemptions of shares. The relevant movements are shown on the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares. In accordance with the Cell's investment objectives, and its risk management policies, the Cell endeavours to invest the subscriptions received in appropriate investments while maintaining sufficient liquidity to meet redemptions, such liquidity being augmented by short-term borrowings or disposal of listed securities where necessary.

To determine the net asset value of the Cell for subscriptions and redemptions, investments have been valued based on the last traded market prices as of the close of business on the relevant trading day.

## 2.10 Increase/(decrease) in net assets attributable to holders of participating redeemable shares from operations

Income not distributed is included in Net Assets Attributable to Holders of Participating Redeemable Shares of the Incorporated Cell's financial statements.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 2. Summary of significant accounting policies (continued)

#### 2.11 Capital risk management

The fair value of the Cell's financial assets and financial liabilities approximate to their carrying amounts at the reporting date. For the purposes of this disclosure, shares are considered to be capital.

The Incorporated Cell's objectives when managing capital is to safeguard its ability to continue as a going concern in order to provide returns for shareholders. There are no externally imposed capital requirements on the Incorporated Cell. The Incorporated Cell has no intention to borrow, other than to fund short term liquidity requirements. The Incorporated Cell may arrange an overdraft facility for such purposes.

#### 2.12 Interest and dividend income

Dividend income is recognised when the right to receive payment is established. All deposit interest and other income is accounted for on an accruals basis.

#### 2.13 Expenses

Expenses are accounted for on an accruals basis and all amounts have been allocated to the Statement of Comprehensive Income.

#### 2.14 Custodian bank charges

Custodian bank charges include additional fees on top of the asking price of the security. The bid-asking spread is not disclosed as part of a custodian bank charge. This spread is included in the Statement of Comprehensive Income within the fair value net gain or loss.

#### 2.15 Taxation

The Cell has been granted Exempt Status under the terms of The Income Tax (Exempt Bodies) (Guernsey) Ordinance, 1989 to income tax in Guernsey. Its liability is an annual fee of £1,200 (2022: £1,200).

The Cell incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income or gains are recorded gross of withholding taxes in the Statement of Comprehensive Income. Withholding taxes are shown as a separate item in the Statement of Comprehensive Income.

#### 3. Financial risk management

#### 3.1 Strategy in using financial instruments

The Cell's activities and investment objectives expose it to a variety of financial risks: market risk (which is made up of price risk, interest rate risk and currency risk), credit risk and liquidity risk (including cash flow risk). The Cell's overall risk management programme seeks to maximise the return derived for the level of risk to which the Cell are exposed and focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Cell's financial performance. The following policies and procedures to mitigate risk have been in place throughout the year.

The Cell will not include any derivative instruments with the exception of:

- Investment in forward foreign currency exchange contracts for the purpose of mitigating exchange rate risk against both the benchmark and the base currency.
- Exchange- traded derivatives for the purpose of risk mitigation within the portfolio.

Derivatives will not be used for speculative purposes or otherwise and unlisted derivative instruments will be limited to forward currency exchange contracts.

The fair value of derivative financial statements as at 30 June 2023 is disclosed under note 9 of the financial statements.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 3. Financial risk management (continued)

### 3.2 Market price risk

Market price risk is the risk that the fair value of future cash flows will fluctuate because of changes in market prices, other than those arising from currency or interest rate risk. The Cell is subject to market price risk as it trades primarily in equities and Collective Investment Schemes. Through its investment in traded securities and instruments the Cell is subject to market movements in equity and bond markets.

All investments present a risk of loss of capital. The Investment Manager moderates this risk through a careful selection of securities and other financial instruments within specified limits. The maximum risk resulting from financial instruments is determined by the fair value of the financial instruments. The Cell's overall market positions are monitored by the Investment Manager and are reviewed by the Board of Directors.

The Cell's market price risk is managed through diversification of the investment portfolio by exposures to varying product categories, hence concentration of risk is minimised. At the year end, the financial assets at fair value through profit or loss, which are subject to market price risk, are as follows:

	2023		202	2
		% of Net		
	Fair Value	Assets	Fair Value	% of Net Assets
	USD		<u>USD</u>	
Government Bonds	2,644,202	21.53	1,752,258	15.32
Collective Investment Schemes	8,452,567	68.80	8,181,078	71.51
Property and Infrastructure Investment Trusts and ETFs	1,150,449	9.36	1,483,438	12.96
	12,247,218	99.69	11,416,774	99.79

The Cell's market price risk is affected by three main components: changes in actual market prices, interest rate and foreign currency movements. Interest rate and foreign currency exchange rate movements are covered in notes 3.3 and 3.5, respectively. If the market indices increased or decreased by 10% with all other variables held constant, the increase or decrease respectively in net assets attributable to holders of participating redeemable shares would amount to:

As at 30 June	2023 Change in	2022 Change in
	Fair Value	Fair Value
	<u>USD</u>	<u>USD</u>
Government Bonds	264,420	175,226
Collective Investment Schemes	845,257	818,108
Property and Infrastructure Investment Trusts and ETFs	115,045	148,344
	1.224.722	1.141.678

#### 3.3 Interest rate risk

The Cell's interest-bearing financial assets and liabilities expose it to risks associated with the effects of fluctuations in the prevailing levels of market interest rates on its financial position and cash flows.

The majority of the Cell's financial assets and liabilities are non-interest bearing. As a result, the Cell is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates. Any excess cash and cash equivalents are invested at short term market interest rates.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 3. Financial risk management (continued)

#### 3.3 Interest rate risk (continued)

The table below summarises the Cell's exposure to interest rate risk. It includes the Cell's assets and trading liabilities at fair values, all of which have contractual re-pricing or maturity dates within one month.

As at 30 June	2023 <u>USD</u>	2022 <u>USD</u>
Net financial assets on which no interest is paid	9,604,171	5,873,263
Net floating rate financial assets	36,969	5,568,256
Net fixed rate financial assets	2,644,202	1,752,258

Should interest rates have increased by 50 basis points with all other variables remaining constant, the increase in the net assets attributable to participating redeemable shareholders would amount to approximately:

As at 30 June	2023 <u>USD</u>	2022 <u>USD</u>
Movement in net floating rate financial assets	185	27,841
Movement in net fixed rate financial assets	13,221	8,761

#### 3.4 Cash flow risk

The Cell holds a significant amount of cash and cash equivalents that expose the Cell to cash flow interest rate risk. The risk exposure here is deemed minimal.

### 3.5 Currency risk

Currency risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign currency exchange rates. The Cell holds assets, including investments, denominated in currencies other than the US Dollar, the functional currency, and therefore it is exposed to currency risk. The exposures are based on the currencies of the underlying assets in the Cell. Where the Cell invests via Collective Investment Funds, the funds are treated as a single asset with its currency of exposure being assumed to be its reporting currency.

The table below summarises the Cell's exposure to currency risks:

As at 30 June	2023	2022
	<u>USD</u>	<u>USD</u>
EUR exposure	1,058	6,478
GBP exposure	1,536,240	1,604,664
ZAR exposure	(1,034)	-
JPY exposure	(9,883)	-

In accordance with the Cell's policies, the Investment Manager monitors the Cell's currency position on a regular basis, and the Board of Directors reviews it periodically. The Cell has the ability to enter into forward foreign exchange contracts in an attempt to mitigate any significant currency risk. Refer to note 9 for more detail.

Should the Cell's functional currency have strengthened, or weakened, by 5% against other currencies to which it is exposed and all other variables, including the price of all investments, had held constant, the net asset attributable to participating redeemable shareholders would have increased, or decreased, as follows:

As at 30 June	2023 <u>USD</u>	2022 <u>USD</u>
EUR exposure	53	324
GBP exposure	76,812	80,233
ZAR exposure	(52)	-
JPY exposure	(494)	-



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 3. Financial risk management (continued)

#### 3.6 Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

There is a risk that an investee company may be unable to satisfy a valid redemption request made by a Cell. The Directors consider that the Investment Manager mitigates this risk by way of its investment process, as described in note 3.2. No such redemption problems have been encountered.

All transactions in listed securities are settled/paid for upon delivery using approved brokers. Delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. Given the relatively short settlement period, and the high credit quality of the brokers used, the risk here is considered to be minimal.

The Cell manages its exposure to credit risk associated with cash deposits by selecting Northern Trust (Guernsey) Limited as the counterparty to hold all cash deposits for the Cell. The Northern Trust Company is a wholly owned subsidiary of the Northern Trust Corporation. The credit rating for Northern Trust Corporation from Standard and Poor's is A+. The credit rating from Moody's is A2.

The Government Bonds held in the portfolio are Aaa and Aa2 rated by Moody's.

The Cell's maximum exposure to credit risk is the carrying value of the assets on the Statement of Financial Position.

#### 3.7 Liquidity risk

Liquidity risk is the risk that the Cell will encounter difficulty in meeting obligations associated with its financial liabilities. The main liquidity risk is the risk that the Cell may be unable to recover funds invested through the usual redemption processes which may result in the Cell having insufficient funds to settle a transaction on the due date. Due to the nature of the Cell, the majority of investments held are in marketable securities that are readily tradable and have reported no warnings regarding its ability to process redemptions as normal.

The Cell has the ability to borrow to meet short term liquidity requirements; however, to date the Cell has not entered into such arrangements.

The table below analyses the Cell's financial assets and financial liabilities into relevant maturity groupings based on the remaining period at the Statement of Financial Position date to the contractual maturity date. The amounts in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances, as the impact of discounting is not significant.

		Between 1		
	Less than 1	and 12	2023	2022
	month	months	Total	Total
		<u>USD</u>	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss	12,247,218	-	12,247,218	11,416,774
Cash and cash equivalents	36,969	-	36,969	-
Securities sold receivable	24,130	-	24,130	167,004
Dividend receivable	1,007	-	1,007	1,025
Interest receivable	14,570	-	14,570	8,055
Deposit interest receivable	120	-	120	
Other receivables	466	-	466	1,757
Fair value of derivative financial instruments	-	-	-	22,215
Due on redemption of participating redeemable shares	-	-	-	(662)
Other payables	(25,663)	-	(25,663)	(24,722)
Fair value of derivative financial instruments	-	(13,475)	(13,475)	-
Securities purchased payable	-	-	-	(4,370)
Bank Overdraft	-	-	-	(145,557)
Net assets attributable to participating redeemable shares	(12,285,342)	-	(12,285,342)	(11,441,519)
Net liquidity position	13,475	(13,475)	-	-



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 3. Financial risk management (continued)

### 3.7 Liquidity risk (continued)

Participating redeemable shares are redeemed on demand at the holder's option. However, the Board of Directors does not envisage that the contractual maturity disclosed in the table above will be representative of the actual cash flows, as holders of these instruments typically retain them for the medium to long term.

#### 3.8 Management of capital

The Board, with the assistance of the Investment Manager, manages the capital of the Cell in accordance with the investment objectives and policies. The Cell's overall strategy remains unchanged.

The Cell has no externally imposed capital requirements.

#### 3.9 Fair value disclosure

In the opinion of the Directors, there are no material differences between the net asset values of the underlying assets and fair values of the financial assets and liabilities.

### 4. Critical accounting estimates and judgments

The fair value of investments is considered to be quoted, active market prices, or prices supplied by the fund administrators of the Cell's underlying investments.

Management makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are outlined below.

The fair value of investments in investee funds that are not quoted in an active market is determined primarily by reference to the latest available redemption price of such units for each investee fund, as determined by the administrator of such investee fund. The Investment Manager may make adjustments to the reported net asset value of various investee funds based on considerations such as:

- the liquidity of the investee fund or its underlying investments;
- the value date of the net asset value provided;
- any restrictions on redemptions; and
- the basis of accounting and, in instances where the basis of accounting is other than fair value, fair valuation information provided by the investee fund's advisors.

The prices are reviewed by the Investment Manager on a periodic basis. The Cell holds no Level 3 investments.

## 5. Portfolio analysis

The Cell's portfolio is organised by focusing on the type of security held and then secondarily by geographical analysis based on the location of the investment.

The Cell operates using the main sector types which are disclosed in note 3.2 and the following main geographical areas:

	2023	2022
	<u>USD</u>	<u>USD</u>
Europe	4,123,699	4,191,068
Guernsey	474,351	624,117
United Kingdom	296,450	325,382
United States	3,063,624	2,143,620
Emerging markets	655,125	969,647
Asia	200,610	291,475
Japan	329,736	234,711
Cayman Islands	2,891,779	2,636,754
Luxembourg	211,844	_
	12,247,218	11,416,774

The geographical segment for listed non-monetary financial assets is considered to be the place of primary listing and for non-listed financial assets where the underlying investment is domiciled.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 6. Financial assets at fair value through profit or loss

	2023	2022
	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss:		
Collective Investment Schemes	8,452,567	8,181,078
Government Bonds	2,644,202	1,752,258
Property and Infrastructure Investment Trusts and ETFs	1,150,449	1,483,438
Total financial assets at fair value through profit or loss	12,247,218	11,416,774
Movement on financial assets at fair value though profit or loss		
Fair value of financial assets at the beginning of the year	11,416,774	11,600,033
Purchases of financial assets	3,252,026	5,315,515
Sales of financial assets	(2,923,105)	(3,794,457)
Realised (losses)/gains on sale of financial assets	(103,252)	147,800
Movement in unrealised gains/(losses) on revaluation of financial assets	604,775	(1,852,117)
Fair value of financial assets at the end of the year	12,247,218	11,416,774
	2023	2022
Comprising:	<u>USD</u>	<u>USD</u>
Cost at the end of the year	12,390,821	12,165,152
Unrealised losses at the end of the year	(143,603)	(748,378)
	12,247,218	11,416,774

IFRS 13 require the Cell to classify fair value hierarchy that reflects the significance of the inputs used in making the measurements. The hierarchy has the following levels:

- Level 1 quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level in the fair value hierarchy, within which the fair value measurement is categorised in its entirety, is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes "observable" requires significant judgement by the Board. The Board considers observable market data that is readily available, readily distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market.

The investments classified as Level 1 consist of financial assets that are actively traded with fair values readily available from recognised exchanges. The Level 1 hierarchy may also include investments in funds that are priced by the underlying administrator where the Cell considers it to be the most advantageous market and would enter into transactions based on those prices.

The investments classified as Level 2 are investments in funds that are actively traded and priced less frequently than monthly but not greater than quarterly for which fair values are obtained from the underlying administrator or fund manager.

The investments classified as Level 3 are investments that are illiquid investments and investments that are traded but priced less frequently than quarterly.



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

### 6. Financial assets at fair value through profit or loss (continued)

The following tables present the Cell's financial assets and financial liabilities measured at fair value by level within the valuation hierarchy as of 30 June 2023 and 30 June 2022:

30 June 2023	Level 1 <u>USD</u>	Level 2 <u>USD</u>	Level 3 <u>USD</u>	Total <u>USD</u>
Financial assets at fair value through profit or loss				
Collective Investment Schemes	8,452,567	-	-	8,452,567
Government Bonds	2,644,202	-	-	2,644,202
Property and Infrastructure Investment Trusts and ETFs	1,150,449	-	-	1,150,449
Financial liabilities at fair value through profit or loss				
Derivative financial instruments	-	(13,475)	-	(13,475)
	12,247,218	(13,475)	-	12,233,743
30 June 2022	Level 1	Level 2	Level 3	Total
	<u>USD</u>	USD	USD	USD
Financial assets at fair value through profit or loss				
Collective Investment Schemes	8,181,078	-	-	8,181,078
Government Bonds	1,752,258	-	-	1,752,258
Property and Infrastructure Investment Trusts and ETFs	1,483,438	-	-	1,483,438
Derivative financial instruments	-	22,215	-	22,215
	11,416,774	22,215	-	11,438,989

There were no movements or reclassifications of investments within the levels of the fair value hierarchy during the years ended 30 June 2023 and 30 June 2022.

The Cell's cash and cash equivalents and short term receivables and payables are recorded at carrying value which approximates fair value.

### 7. Cash and cash equivalents

Management shares receivable

For the purposes of the Statement of Cash Flows, cash and cash equivalents comprise the following balances with original maturity of less than 90 days:

	2023 <u>USD</u>	2022 <u>USD</u>
Cash at bank/(Overdraft)	36,969	(145,557)
	36,969	(145,557)
8. Other receivables		
	2023	2022
	<u>USD</u>	<u>USD</u>
Prepayments	466	1,757

100 **1,857** 

100



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 9. Fair value of derivative financial instruments

Forward foreign exchange contracts designated as at fair value through profit or loss:

		Maturity	Contract	Closing	Contract	Market	Financial
30 June 2023	Amount CCY	date	rate	rate	value	value	liability
Outstanding contract to sell GBP Outstanding contract to sell	GBP99,170	10/08/2023	0.790666	0.7865654	(125,426)	(126,080)	(654)
GBP Outstanding contract to buy	GBP780,000	10/08/2023	0.788903	0.7865654	(988,715)	(991,653)	(2,938)
JPY	JPY 16,700,000	10/08/2023	133.146142	144.5350000	125,426	115,543	(9,883) (13,475)
30 June 2022	Amount CCY	Maturity date	Contract rate	Closing rate	Contract value	Market value	Financial asset/(liability)
Outstanding contract to sell GBP Outstanding contract to buy	GBP783,932	24/08/2022	0.794970	0.8234184	(986,115)	(952,046)	34,069
JPY	JPY 31,000,000	24/08/2022	0.007846	0.0074631	243,211	231,357	(11,854) 22,215

In accordance with the Cell's investment objectives, the Cell may enter into forward foreign exchange contracts to hedge foreign currency movements they may be exposed to through its investment portfolio. As there is no assurance that these hedges will be effective in achieving the offsetting of changes in cash flows attributable to currency risk on these investments, it is the policy of the Cell not to apply hedge accounting.

For foreign exchange contracts, the Cell pays a specified amount in one currency and receives a specified amount in another currency. Foreign exchange contracts are simultaneously settled gross and are presented on the Statement of Financial Position at their fair value.

#### 10. Other payables

	2023 <u>USD</u>	2022 <u>USD</u>
Management fee payable	3,025	3,000
Custodian fee payable	1,403	2,429
Investment management fee payable	4,014	4,007
Audit fee payable	9,407	8,010
Distribution fee payable	4,032	3,177
Sundry expenses payable	3,782	4,099
	25,663	24,722

## 11. Share capital

The Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

Management Shares in Issue			30.06.23	30.06.22
			<u>USD</u>	<u>USD</u>
Management shares			100	100
	Class A	Class C	Total	Class A & C
	Year ended	Year ended	Year ended	Year ended
Participating Redeemable Shares in Issue	30.06.23	30.06.23	30.06.23	30.06.22
Balance at the beginning of the year	11,065,256	774,444	11,839,700	10,950,599
Issue of participating redeemable shares	128,399	926,982	1,055,381	2,420,358
Redemption of participating redeemable shares	(510,257)	(2,925)	(513,182)	(1,531,258)
Balance at the end of the year	10,683,398	1,698,501	12,381,899	11,839,699



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

## **Notes to the Financial Statements**

#### 12. Net asset value per participating redeemable share

		Net assets	
As at 30 June	NAV per share 2023 <u>USD</u>	attributable 2023 <u>USD</u>	Shares in issue 2023
Class A	1.01	10,752,685	10,683,398
Class C	0.90	1,532,657	1,698,501
Total		12,285,342	12,381,899
	NAV per	Net assets	
	NAV per share	Net assets attributable	Shares in issue
As at 30 June	•		Shares in issue 2022
As at 30 June	share	attributable	
As at 30 June Class A	share 2022	attributable 2022	
	share 2022 <u>USD</u>	attributable 2022 <u>USD</u>	2022

#### 13. Dividends payable to participating redeemable shareholders

No dividends were paid during the year (2022: Nil) and the Board does not intend to pay any dividends. All available income will be reinvested.

#### 14. Related-party transactions

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions.

### 14.1 Management and Administration fee

The Cell are managed by Momentum Wealth International Limited (the "Manager"), a management company incorporated in Guernsey, providing management services to the Cell under the terms of the management agreement in place.

The Manager is entitled to receive the following Management and Administration fee, will accrue as at each valuation point, based on the current valuation of the Cell and is payable monthly in arrears and subject to a minimum annual fee of USD 22,000 and chargeable on a sliding scale in respect of the Cell, as follows:

Fee - % of NAV per annum	<u>Cell NAV</u>
0.30%	Up to USD60m
0.25%	Over LISDEOm

The Administrator is entitled to such remuneration as agreed between the Manager and the Administrator from time to time and such remuneration is paid by the Manager out of the Management and Administration Fee received from the

Management and Administration Fee charged during the year and accrued at year end:

	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	36,159	38,499
Accrued at year end	3,025	3,000



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 14. Related-party transactions (continued)

#### 14.2 Investment Management fee

The Manager has appointed an Investment Manager, Momentum Global Investment Management Limited, a UK registered company, to manage the investment portfolio of the Cell. The Investment Manager is entitled to receive a fee (the "Investment Management fee") which will accrue as at each Valuation Point, based on the current aggregate valuation of the Cell of the Company in respect of which the Distribution Partner is appointed and is payable monthly in arrears and chargeable on a sliding scale in respect of all Share Classes, as follows:

Fee - % of NAV per annum	<u>Cell NAV</u>
0.35%	Up to USD30m
0.30%	From USD30m to USD 60m
0.25%	Over USD60m

Investment Management fee is subject to a minimum fee of USD30,000 per annum for the Cell, which will be borne by the Classes on a pro rata basis by reference to their respective NAVs.

Investment Management fees charged during the year and accrued at year end:

	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	42,186	44,887
Accrued at year end	4,014	4,007

#### 14.3 Custodian fee

The Cell has engaged the services of Northern Trust (Guernsey) Limited to provide custodian services. The Custodian is entitled to the payment of a fee (the "Custodian fee") for the services rendered in connection with the Cell. The Custodian Fee will accrue as at each Valuation Point, based on the current valuation and is payable monthly in arrears., subject to a minimum of USD8,000 per annum. Additional transaction fees may also apply.

Fee - % of NAV per annum		Cell NAV
0.05%		Up to USD30m
0.04%	Over USD30n	n up to USD 60m
0.03%	Over USD60m	up to USD100m
0.02%		Over USD100m
Custodian fees charged during the year and accrued at year end:		
	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	7,813	12,072
Accrued at year end	1,403	2,429



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

### 14. Related-party transactions (continued)

#### 14.4 Distribution Partner fee

The Cell has appointed PMK Consulting Services (Pty) Ltd as distribution partner to promote and market the Cell. The Distribution Partner is entitled to receive a fee equal to 0.35% of the NAV of the Cell attributable to the Class A USD Share per annum and 0.75% of the NAV of the Cell attributable to the Class C USD Shares per annum (the "Distribution Partner fee"). The Distribution Partner Fee will accrue as at each Valuation Point, based on the current valuation and is payable monthly in arrears. The Distribution Partner will also be entitled to be paid any expenses and disbursements reasonably incurred in performance of its duties.

Distribution Partner fee charged during the year and accrued at the year end:

	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	47,837	46,563
Accrued at year end	4,032	3,177

#### 14.5 Board of Directors' remuneration

The Directors' fees in respect of the Incorporated Cell shall not exceed USD20,000 or currency equivalent in any 12-month period. In addition, the Directors shall be entitled to be repaid for all reasonable out of pocket expenses properly incurred by them in the performance of their duties to the Cell. Such fees and expenses shall be paid out of the assets of the Cell alone and not from the cellular assets of other Cells of the Company or assets of the Company itself.

The Directors waived their right to a fee in 2023 (2022: Nil).

## 15. Ultimate controlling party

In the opinion of the Directors, on the basis of the shareholdings advised to them, the Cell has no ultimate controlling party.

#### 16. Reconciliation of published valuation to financial statements

	2023	2022
	<u>USD</u>	<u>USD</u>
Net assets attributable to holders of participating redeemable shares Adjustments:	12,285,342	11,441,519
Adjustment to accrue for rebranding of financial statements	-	441
Accrued dividend income	-	(1,025)
Adjustment to fair value of derivatives financial instruments	344	(3,300)
Adjustment in value of assets at financial assets at fair value through profit and loss	(41,470)	25,095
Net assets attributable to holders of participating redeemable shares	12,244,216	11,462,730
NAV per Class A share per published valuation	1.00	0.97
NAV per Class C share per published valuation	0.90	0.88
NAV per Class A share per financial statements	1.01	0.97
NAV per Class C share per financial statements	0.90	0.88



## Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

### 17. Subsequent events

These financial statements were approved for issuance by the Board on 30 November 2023. Subsequent events have been evaluated until this date.

On the 1 July 2023, amendments were made to the Supplemental Prospectus of the Cell in relation to the issuing of Class B USD Shares and the following amendments were made, and were effective from that date in relation to these shares:

- B USD Shares will be issued at USD1 during the initial offer period and at NAV following that period;
- They are only available for investment by collective investment schemes which are also distributed by the Distribution Partner and such other persons as the Directors may determine from time to time;
- In respect of the Class B USD Shares the Investment Management Fee will be chargeable on a sliding scale as follows:

Fee - % of NAV per annum	<u>Cell NAV</u>
0.25%	Up to USD15m
0.20%	Over USD15m

- The minimum Investment Management Fee of USD30,000 will be borne by the Classes on a pro rata basis by reference to their respective NAVs.
- In respect of Class B USD Shares, no Distribution Fee will be payable by the Cell.

No further significant events have occurred in respect of the Cell that are considered material to the understanding of these audited financial statements.